Skip to main content
main-content

30-10-2018 | Castration-resistant prostate cancer | ESMO 2018 | Video

Abiraterone alone likely suppresses testosterone sufficiently in mCRPC patients

Carsten Ohlmann discusses findings of the phase II SPARE trial that investigated forgoing LHRH therapy in metastatic prostate cancer patients receiving abiraterone acetate (5:16).

Please log in to get access to this content

More on this topic

GU cancers in the 2020 ASCO Virtual Scientific Program

All the news and expert video interviews from the virtual meeting

Image Credits